Rapid AML Panel

Mutations in the FLT3 gene are common mutations in acute myeloid leukemia (AML). This assay detects internal tandem duplication (ITD) mutations and mutations in the tyrosine kinase domain (TKD) of FLT3. Presence of these mutations in AML provide prognostic information and can aid in the determination of therapeutic regimen.

FLT3 is a receptor tyrosine kinase (RTK) that dimerizes on binding its ligand, the cytokine FLT3 ligand (FL), which then undergoes autophosphorylation, and transduces signals downstream (STAT, AKT, ERK) that promote proliferation and survival. Activating mutations of FLT3 are common mutations found in AML. A particular form of FLT3 is mutated by duplicating coding sequence derived from the juxtamenbrane domain inserted in tandem (internal tandem duplication (ITD). These FLT3-ITD mutations result in the constitutive activation of the tyrosine kinase function. Patients with FLT3-ITD mutations have increased relapse rates and reduced overall survival. Point mutations in the activation loop of the kinase domain, most commonly at the residue Asp 835 (D835), also known as tyrosine kinase domain (TKD) mutations, also result in the constitutive activation of the FLT3 kinase. Signaling from FLT3-TKD mutations does not appear as abnormal, and the prognostic impact appears to be less severe when compared with ITD mutations (FLT3-ITD mutations are found in approximately 23% of AML cases, whereas TKD mutations are found in 7%).

NPM1 (nucleophosmin) mutation is one of the most common recurring genetic lesions in acute myeloid leukemia (AML). This AML type frequently has myelomonocytic or monocytic features and typically presents de novo in older adults with a normal karyotype. Prevalence increases with age, occurring in 2% to 8% of childhood AML and 27% to 35% of adult AML. The most common mutations a 4 bp duplication at c.860_863 (exon 11) or insertion at c.863_864 (exon 11), accounts for 90% to 95% or NPM1 mutations. NPM1 mutations in absence of FLT3-ITD identify a prognostically favorable subgroup.

IDH 1/2 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes in human cancer. They encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to a-ketoglutarate (aKG), a key component in metabolic and cellular pathways including the Krebs cycle. IDH1 and IDH2 mutations are found in multiple types of human cancer including, but not limited to, acute myeloid leukemia and gliomas. Identification of IDH mutations can aid in their diagnosis, provide prognostic information and suggest treatment with IDH inhibitors. This assay will detect mutations affecting amino acids 100 and 132 of IDH1 and amino acids 140 and 172 of IDH2.

Please direct any questions regarding this test to customer service at 800-345-4363.

The FLT3 PCR assay is capable of detecting a mutant cell population with a sensitivity of five mutant cells per 100. The NPM1 assay has a sensitivity to detect approximately 5% population of cells containing the 4 bp duplication or insertion in exon 11 in a background of nonmutant cells. This assay will not detect the mutation below the sensitivity of this assay or other NPM1 mutations.

IDH1/2 SNaPshot vitro studies indicate that this assay has a sensitivity to detect approximately 5% mutated IDH1/2 in a background of nonmutant DNA. Mutations present at a level below the detection sensitivity or outside the analyzed region of the IDH1 and IDH2 genes will not be detected by this assay.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

• FLT3: Polymerase chain reaction (PCR); restriction enzyme digest; capillary electrophoresis
• NPM1: Polymerase chain reaction (PCR); capillary electrophoresis
• IDH1/2 SNaPshot: Multiplex PCR (primer extension-based method)

• Sample Report

Clark O, Yen K, Mellinghoff IK. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res. 2016 Apr 15;22(8):1837-1842. PubMed 26819452

Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016 Apr;27(4):599-608. PubMed 27005468

Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute Myeloid Leukemia Carrying Cytoplasmic/Mutated Nucleophosmin (NPMc+ AML): Biologic and Clinical Features. Blood. 2007 Feb 1;109(3): 874-885. PubMed 17008539

FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML. U.S. food & Drug Administration (FDA) website: https://www.fda.gov/Drugs/InformationonDrugs/ApprovedDrugs/ucm569482.htm. Updated August 1, 2017. Accessed April 2025.

Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017 Feb;31(2):272-281. PubMed 27721426

Mrozek K, Bloomfield CD, Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-177. PubMed 17124057

NCCN Guidelines: Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) website: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411. Accessed April 2025.

Ohgaki H1, Kleihues P. The definition of primary and secondary gliobastoma. Clin Cancer Res. 2013 Feb 15;19(4):764-772. PubMed 23209033

Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2017 Feb 2;129(5):565-571. PubMed 27872057

Schlenk RF, Döhner K, Krauter J, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med. 2008 May;358(18):1909-1918. PubMed 18450602

Schneider F, Hoster E, Unterhalt M, et al. NPM1 But Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients With Normal Karyotype AML (NK-AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood. 2009 May 21;113(21):5250-5253. PubMed 19279329

Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations Nucleophosmin (NPM1) in Acute Myeloid Leukemia (AML): Association With Other Gene Abnormalities and Previously Established Gene Expression Signatures and Their Favorable Prognostic Significance. Blood. 2005 Dec 1;106(12):3747-3754. PubMed 16109776

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-773. PubMed 19228619